Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00152386 · ClinicalTrials.gov registry record · Phase 3
A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 950
- Enrollment target
NCT00152386: Completed Phase 3 study, sponsored by UCB Pharma.
NCT00152386 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 950 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (23% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00152386, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 950 participants
- Enrollment target
Study Summary
Patients will be assigned to one of three treatment groups. Study medication is administered over a 52 week study duration.
Interventions
- DRUG Certolizumab pegol (CDP870)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 950 participants |
| Start Date | 2005-02 |
| Est. Completion | 2006-10 |
| Phase | Phase 3 |
What the finished NCT00152386 record still lists
NCT00152386 is an interventional study that assigns participants to a tested intervention. The registered 950 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (23% higher).
The record links to 0 conditions, and to 1 intervention - of which Certolizumab pegol (CDP870) is the first listed.
NCT00152386 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00152386 about?
NCT00152386 is a clinical study titled "A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis". Patients will be assigned to one of three treatment groups. Study medication is administered over a 52 week study duration.
What is the current status of trial NCT00152386?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 950 participants. The study started on 2005-02. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00152386?
The interventions under investigation include: Certolizumab pegol (CDP870) (DRUG).
Who is sponsoring clinical trial NCT00152386?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00152386's enrollment target sits among peer trials
950 333rd of 2000 higher than 1,667 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03784924 · 950 participants
EDRN Prostate MRI Biomarker Study
- NCT04180930 · 950 participants
An Evaluation of Two PTSD Assessments in an Active Duty and Military Veteran Sample
- NCT04895709 · 949 participants · Phase 1
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
- NCT04375033 · 952 participants · Phase 4
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia